MODERNA(#MODERNA) weekly uptrend special report based On 1 Lot Calculation:
GLOBAL PHARMACEUTICAL INDUSTRY:
- THE GLOBAL PHARMACEUTICAL INDUSTRY IS CURRENTLY WORTH ~$1.11T: According to the most recent reports, the Pharmaceutical industry is worth approximately $1.11T. The pharmaceutical industry is one of the largest industries in the world, which provides products that deal with infectious diseases and various illnesses.
- MARKET POTENTIAL: THE PHARMACEUTICAL INDUSTRY IS EXPECTED TO GROW TO A $2.13T DOLLAR MARKET BY 2026: Analysts are forecasting, that at the current rate of growth, the pharmaceutical industry could be expected to reach $2.13trillion in value. Analysts highlight that this represents an industry compounded annual growth of 7.7% a year.
THE COMPANY
- Moderna is a clinical stage biotechnology company, it provides development of messenger RNA therapeutics and vaccines. Development of these messenger RNA solutions is primarily focused on infectious, immuno-oncological and cardiovascular diseases.
PART OF MODERNA’S VACCINE PIPELINE:
- RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE (PHASE 3): According to the US Centers for Disease Control and Prevention, Respiratory syncytial virus, or RSV, is a common respiratory virus that usually causes mild, cold-like symptoms. Most people recover in a week or two, but RSV can be serious, especially for infants and older adults. RSV is the most common cause of bronchiolitis (inflammation of the small airways in the lung) and pneumonia (infection of the lungs) in children younger than 1 year of age in the United States. POTENTIAL MARKET: The RSV causes around 33 million cases globally per year, with no vaccine currently available to treat the disease. Should Moderna be the first to market with their RSV vaccine, they could have a strong market share and potential to generate significant revenues with their product. MODERNA’S ADVANTAGE: Moderna gains advantage over Pfizer and Glaxo SmithKlinefor its RSV vaccine after successful Phase 3. Moderna’s RSV vaccine was 83.7% effective against RSV-associated lower respiratory diseases. The positive results gave Moderna the breakthrough therapy designation from the Food and Drug Administration ahead of key competitors Pfizer and GSK in this space. This could enable Moderna to deliver the vaccine to market ahead of its competitors.
- COVID+FLU VACCINE (PHASE 1)
- FLU VACCINE (PHASE 3)
- PERSONILISED CANCER VACCINE (PCV) (PHASE 2). A combination of Moderna's personalized cancer vaccine and Merck & Co's blockbuster immunotherapy Keytruda cut the risk of recurrence or death of the deadliest skin cancer by 44% compared with Keytruda alone in a mid-stage trial.
- HIV VACCINE (PHASE 1)
EVENTS AND ANALYSIS:
- EVENT Q4 2022 EARNINGS (February 23, 2023 CONFIRMED: PREMARKET): Moderna is expected to report a Q4 revenue of $5.00B and an Earnings Per Share of $4.63. This would be a revenue increase of around 49% compared with Q3. Also, this would be an increase of around 73% compared to Q3. Company revenue on an annual basis is forecast to come in at its highest ever levels at $19.1B.
- ANALYSTS OPINIONS: Goldman Sachs has a price target of $302, Jefferies target is $275 while Deutsche Bank targets $225. The Bloomberg Analyst Consensus has an average price target of $215.33.
- STOCK PRICE ACTION: THE STOCK HAS HAD A DOWNWARD CORRECTION OF AROUND 77.40% FROM ITS RECENT ALL- TIME HIGH OF $498.28 (August, 2021). The stock has fallen to its lowest rate since January 2021, to $114.75 (September 2022). Moderna was last trading around $166, and If a full recovery follows recent all- time highs, the stock could see an upside of around ~200%. However, the price could go lower.
Moderna, February 9, 2023
Current Price:165.00
Moderna |
Weekly |
Trend direction |
|
300.00 |
|
250.00 |
|
200.00 |
|
140.00 |
|
130.00 |
|
120.00 |
Example of calculation based on weekly trend direction for 1 Lot1
Moderna |
||||||
Pivot Points |
||||||
Profit or loss in $ |
135,000.00 |
85,000.00 |
35,000.00 |
-25,000.00 |
-35,000.00 |
-45,000.00 |
Profit or loss in €2 |
124,758.57 |
78,551.69 |
32,344.81 |
-23,103.44 |
-32,344.81 |
-41,586.19 |
Profit or loss in £2 |
109,577.92 |
68,993.51 |
28,409.09 |
-20,292.21 |
-28,409.09 |
-36,525.97 |
Profit or loss in C$2 |
184,445.10 |
116,132.10 |
47,819.10 |
-34,156.50 |
-47,819.10 |
-61,481.70 |
- 1.00 lot is equivalent of 1 000 units
- Calculations for exchange rate used as of 09:20 (GMT) 09/02/2023
Fortrade recommends the use of Stop-Loss and Take-Profit, please speak to your Senior Account ManagerClient Manager regarding their use.
- You may wish to consider closing your position in profit, even if it is lower than suggested one
- Trailing stop technique can protect the profit – Ask your Senior Account ManagerClient Manager for more detail